The semaglutide vs tirzepatide comparison, now joined by the triple agonist retatrutide, sits at the centre of modern metabolic research. All three are lipidated peptides that act on incretin and related hormone receptors, but each engages a different combination of receptors. This guide explains their structure, pharmacology and how laboratories design comparison studies. All three compounds are available from Peptide Sciences for laboratory research use only.
Semaglutide vs Tirzepatide vs Retatrutide at a Glance
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor targets | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + glucagon |
| Class | Single agonist | Dual agonist | Triple agonist |
| Backbone | GLP-1 based | GIP based | GIP based |
| Half-life extension | C18 fatty diacid + albumin binding | C20 fatty diacid + albumin binding | Fatty diacid + albumin binding |
| Typical research focus | Benchmark GLP-1 pharmacology | Added value of GIP signalling | Effect of glucagon-receptor activity on energy expenditure |
Background: Incretin Hormones
Incretins are gut hormones released after a meal that amplify glucose-dependent insulin secretion. The two main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Native GLP-1 is broken down by the enzyme DPP-4 within minutes, so research analogues are engineered for enzymatic resistance and long circulation. Glucagon, while not an incretin, is a related pancreatic hormone that raises hepatic glucose output and energy expenditure.
Semaglutide: The GLP-1 Benchmark
Semaglutide shares about 94% sequence homology with human GLP-1. An aminoisobutyric acid (Aib) at position 8 blocks DPP-4 cleavage, and a C18 fatty-diacid side chain promotes reversible albumin binding, extending its half-life to roughly a week. In the lab, it is the standard reference GLP-1 receptor agonist for studies of insulin secretion, gastric emptying and hypothalamic appetite signalling. Research vials include Semaglutide 3mg, 6mg and 10mg.
Tirzepatide: Adding GIP Receptor Activity
Tirzepatide is a 39-amino-acid peptide built on the GIP sequence and modified to activate the GLP-1 receptor as well. It shows stronger potency at the GIP receptor than at the GLP-1 receptor (so-called imbalanced agonism), and its GLP-1 receptor signalling is biased toward cAMP over beta-arrestin recruitment. Researchers use tirzepatide to ask a central question: does GIP activity add to GLP-1 effects in adipose tissue, beta cells and the brain? Formats include Tirzepatide 5mg, 10mg and 15mg.
Retatrutide: The Triple Agonist
Retatrutide (LY3437943) adds glucagon-receptor agonism to GIP and GLP-1 activity. In preclinical models, glucagon signalling is associated with increased energy expenditure and hepatic fat oxidation, while incretin signalling reduces food intake. Retatrutide therefore lets researchers study how combining intake-reducing and expenditure-raising mechanisms changes metabolic outcomes. Available as Retatrutide 6mg, 12mg and 16mg.
How Labs Compare Incretin Peptides
In-Vitro Receptor Studies
- cAMP accumulation assays in cells expressing GLP-1R, GIPR or GCGR.
- Beta-arrestin recruitment assays to measure signalling bias.
- Receptor internalisation and desensitisation experiments.
Animal Models
- Diet-induced obesity rodent models measuring food intake, body composition and energy expenditure.
- Glucose and insulin tolerance tests.
- Liver fat and lipid-profile endpoints in metabolic-dysfunction models.
Good Study Design Practice
Comparative studies should use concentrations matched by receptor potency rather than mass alone, include vehicle controls, keep each peptide on a single documented lot, and account for differences in half-life when choosing sampling time points.
Related Compounds
Researchers studying incretin biology often include cagrilintide, a long-acting amylin analogue frequently combined with semaglutide, and the oral small-molecule GLP-1 agonist orforglipron, which allows peptide and non-peptide comparisons. Browse the full weight loss peptides collection for more.
Handling Lipidated Peptides
Fatty-acid–modified peptides can adsorb to plastic surfaces and may aggregate at high concentrations. Use low-binding tubes, avoid vigorous shaking, and store lyophilised vials cold and protected from light. See our peptide storage guide for details.
Summary
Semaglutide is the single-receptor GLP-1 benchmark, tirzepatide adds GIP receptor activity, and retatrutide adds glucagon receptor activity on top of both. Comparing them lets researchers separate the contribution of each hormone pathway. For the published literature, search tirzepatide and semaglutide on PubMed. All Peptide Sciences products are for laboratory research only and are not for human or veterinary use.
